Cargando…

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy

Although the blockade of the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway has become a promising treatment strategy for several types of cancers, the constitutive activation of c-Met in tumors may cause a low overall response rate to PD-1 inhibitors. Increasing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Qingyun, Liang, Qiaoyan, Sun, Zujun, Yuan, Xingxing, Hou, Weihua, Wang, Yuxiong, Wang, Huijie, Yu, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296967/ https://www.ncbi.nlm.nih.gov/pubmed/34350059 http://dx.doi.org/10.1080/2162402X.2021.1914954

Ejemplares similares

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity
por: Asano, Ryutaro, et al.
Publicado: (2018)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats
por: Asano, Ryutaro, et al.
Publicado: (2020)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma
por: Ma, Yilan, et al.
Publicado: (2019)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

Jet/MET + b/c tagging
por: Komaragiri, Jyothsna Rani
Publicado: (2022)

Isothiocyanatostilbenes as novel c-Met inhibitors
por: Gray, Alana L., et al.
Publicado: (2015)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

c-Met and miRs in Cancer
por: Giglio, Simona, et al.
Publicado: (2015)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
por: Jarantow, Stephen W., et al.
Publicado: (2015)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

Computational study on novel natural inhibitors targeting c-MET
por: Hou, Yuanyuan, et al.
Publicado: (2021)

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
por: Wang, Ying, et al.
Publicado: (2016)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Aptamers Binding to c-Met Inhibiting Tumor Cell Migration
por: Piater, Birgit, et al.
Publicado: (2015)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
por: Ma, Xiao-Lu, et al.
Publicado: (2023)

c-Met is essential for wound healing in the skin
por: Chmielowiec, Jolanta, et al.
Publicado: (2007)

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

HGF/c-MET Signaling in Melanocytes and Melanoma
por: Czyz, Malgorzata
Publicado: (2018)

Structural basis of the activation of c-MET receptor
por: Uchikawa, Emiko, et al.
Publicado: (2021)

c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
por: Lux, Alexander, et al.
Publicado: (2019)

PD-L1 and c-MET expression and survival in patients with small cell lung cancer
por: Miao, Lulu, et al.
Publicado: (2017)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
por: Kang, Chung Hyo, et al.
Publicado: (2021)

An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma
por: Gao, Shan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_frlpnl3419j1jjb3ue8gvi83ed